Cardiovascular Risk in Children With Chronic Conditions Study
Launched by SEMMELWEIS UNIVERSITY · Jul 17, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at children and young adults with long-term health conditions that might raise their chances of heart and blood vessel problems early in life. The researchers want to understand why these problems happen and how tiny blood vessels in the body might already show signs of damage long before any serious heart issues appear. They also plan to use new computer technology, called artificial intelligence (AI), to help spot early warning signs and improve care tailored to each person’s needs.
The study is open to boys and girls aged 6 to 25 who have certain chronic health conditions, like kidney or liver transplants, diabetes, high blood pressure, obesity, or some types of cancer, among others. Participants need to agree to take part (or have a parent or guardian agree if they’re under 18). People with very serious health problems, ongoing chemotherapy, or certain infections won’t be able to join. If you take part, you can expect to have some tests and check-ups to help doctors learn more about heart health risks and how to catch problems early, so they can provide better care in the future.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Individuals aged between 6 and 25 years;
- • 2. Diagnosed with a chronic childhood condition/disease associated with an increased risk of early cardiovascular disease;
- • 3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.
- • Chronic childhood conditions/diseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https://doi.org/10.1161/CIR.0000000000000618), as well as other conditions/diseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.
- Exclusion criteria:
- • 1. Severe intellectual and developmental disability;
- • 2. Decompensated heart failure;
- • 3. Severe primary immunodeficiency;
- • 4. Ongoing intravenous chemotherapy;
- • 5. Infectious diseases posing a public health risk; or
- • 6. History of regular alcohol or drug use.
About Semmelweis University
Semmelweis University, located in Budapest, Hungary, is a prestigious institution renowned for its commitment to advancing medical education, research, and healthcare innovation. As a prominent clinical trial sponsor, the university leverages its extensive expertise in various medical fields to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing therapeutic strategies. With a focus on ethical standards and scientific excellence, Semmelweis University collaborates with a network of healthcare professionals and researchers to translate groundbreaking discoveries into practical applications, ultimately contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Budapest, , Hungary
Patients applied
Trial Officials
Tamas Kiss, MD, PhD
Principal Investigator
Semmelweis University, Pediatric Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported